| scholarly article | Q13442814 |
| P2093 | author name string | L Chen | |
| J Chen | |||
| W Lu | |||
| R Zhang | |||
| W Zhou | |||
| S Agrawal | |||
| P2860 | cites work | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 | Q24328775 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules | Q28248180 | ||
| DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 | Q28254119 | ||
| Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Mapping of the p53 and mdm-2 Interaction Domains | Q28609886 | ||
| Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 | Q29617850 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. | Q30428424 | ||
| Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis | Q33886271 | ||
| Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo | Q33886276 | ||
| Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. | Q33888123 | ||
| Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors | Q34330309 | ||
| Database of p53 gene somatic mutations in human tumors and cell lines | Q34868968 | ||
| Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage | Q35671727 | ||
| The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. | Q35773674 | ||
| Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line | Q35926080 | ||
| Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage | Q36557538 | ||
| DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways | Q36647845 | ||
| The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth | Q36659029 | ||
| Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion | Q37142419 | ||
| Wild-type p53 is a cell cycle checkpoint determinant following irradiation | Q37152060 | ||
| Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. | Q41063629 | ||
| mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway | Q41070621 | ||
| p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts | Q41654913 | ||
| Induction of Mdm2 and enhancement of cell survival by bFGF. | Q42833951 | ||
| p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. | Q54202935 | ||
| Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells | Q72124534 | ||
| Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas | Q72769128 | ||
| Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells | Q72883634 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 21-34 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression | |
| P478 | volume | 5 |
| Q34116228 | ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage |
| Q40827743 | ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation |
| Q28366563 | Activation and activities of the p53 tumour suppressor protein |
| Q35153742 | Antisense therapeutics: from theory to clinical practice |
| Q33826614 | Antisense therapeutics: is it as simple as complementary base recognition? |
| Q73594102 | Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene |
| Q34010863 | Concurrent overexpression of serum p53 mutation related with Helicobacter pylori infection. |
| Q37283483 | Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. |
| Q40068515 | Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates |
| Q46197811 | E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines |
| Q52746431 | Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. |
| Q53361873 | Expression of MDM2 protein and mRNA in condyloma acuminata. |
| Q37097416 | Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy |
| Q47157561 | In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell |
| Q33621929 | Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions |
| Q36201740 | Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. |
| Q44849807 | Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. |
| Q81099539 | Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables |
| Q24813658 | Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells |
| Q35036565 | RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer |
| Q33807793 | Regulation of p53 stability |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q34076012 | Strategies for manipulating the p53 pathway in the treatment of human cancer. |
| Q78353663 | Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells |
| Q35903526 | Targeting the p53-MDM2 interaction to treat cancer |
| Q74200562 | The contribution of the RING finger domain of MDM2 to cell cycle progression |
| Q33786947 | The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress |
| Q40616229 | Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling |
Search more.